Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Infant Neuroblastoma Study Group - 1999
- Registration Number
- NCT00025649
- Locations
- 🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇫🇷Centre Hospitalier Regional de Purpan, Toulouse, France
🇳🇴Rikshospitalet University Hospital, Oslo, Norway
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Infant Neuroblastoma Study Group - 1999
- Registration Number
- NCT00025610
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇦🇹St. Anna Children's Hospital, Vienna, Austria
🇧🇪Universitair Ziekenhuis Gent, Ghent, Belgium
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Infant Neuroblastoma Study Group - 1999
- Registration Number
- NCT00025623
- Locations
- 🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇨🇭Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
🇫🇷Centre Hospitalier Regional de Purpan, Toulouse, France
High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Registration Number
- NCT00004921
- Locations
- 🇩🇪
Klinikum Nuernberg - Klinikum Nord, Nuernberg, Germany
🇮🇹Ospedale San Bortolo, Vicenza, Italy
🇦🇹Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Infant Neuroblastoma Study Group - 1999
- Registration Number
- NCT00025597
- Locations
- 🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇳🇴Rikshospitalet University Hospital, Oslo, Norway
🇬🇧Bristol Royal Hospital for Children, Bristol, England, United Kingdom
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT00004092
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 428
- Registration Number
- NCT00002944
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT00004876
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Lobradimil and Carboplatin in Treating Children With Brain Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019422
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States
🇺🇸Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 80
- Registration Number
- NCT00003732
- Locations
- 🇩🇰
Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.